MX2013011336A - Composiciones farmaceuticas intranasales de benzodiazepina. - Google Patents

Composiciones farmaceuticas intranasales de benzodiazepina.

Info

Publication number
MX2013011336A
MX2013011336A MX2013011336A MX2013011336A MX2013011336A MX 2013011336 A MX2013011336 A MX 2013011336A MX 2013011336 A MX2013011336 A MX 2013011336A MX 2013011336 A MX2013011336 A MX 2013011336A MX 2013011336 A MX2013011336 A MX 2013011336A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
intranasal
intranasal benzodiazepine
benzodiazepine pharmaceutical
benzodiazepine
Prior art date
Application number
MX2013011336A
Other languages
English (en)
Other versions
MX357800B (es
Inventor
Moise A Khayrallah
Myoung-Ki Baek
Jae-Hoon Jo
Hye-Jin Chang
Gary Bream
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2013011336A publication Critical patent/MX2013011336A/es
Publication of MX357800B publication Critical patent/MX357800B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Abstract

La presente invención se refiere generalmente a composiciones farmacéuticas intranasales que comprenden una benzodiazepina y métodos de uso de las mismas, que pueden proveer un efecto terapéutico sin una disminución en la presión sanguínea y/o el pulso después de la administración de la composición farmacéutica.
MX2013011336A 2011-03-31 2012-03-30 Composiciones farmacéuticas intranasales de benzodiazepina. MX357800B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469940P 2011-03-31 2011-03-31
PCT/US2012/031453 WO2012135619A2 (en) 2011-03-31 2012-03-30 Intranasal benzodiazepine pharmaceutical compositions

Publications (2)

Publication Number Publication Date
MX2013011336A true MX2013011336A (es) 2013-12-16
MX357800B MX357800B (es) 2018-07-25

Family

ID=46928023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011336A MX357800B (es) 2011-03-31 2012-03-30 Composiciones farmacéuticas intranasales de benzodiazepina.

Country Status (16)

Country Link
US (3) US20120252793A1 (es)
EP (1) EP2691100A4 (es)
JP (1) JP2014509655A (es)
KR (1) KR20140029426A (es)
CN (1) CN103619338B (es)
AR (1) AR085927A1 (es)
AU (1) AU2012236334B2 (es)
BR (1) BR112013024968A2 (es)
CA (1) CA2831308A1 (es)
HK (1) HK1195252A1 (es)
MX (1) MX357800B (es)
PH (1) PH12017501688A1 (es)
RU (2) RU2013148120A (es)
SG (2) SG193958A1 (es)
TW (1) TWI601532B (es)
WO (1) WO2012135619A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5929800B2 (ja) * 2012-04-03 2016-06-08 コニカミノルタ株式会社 定着液および画像形成方法
JP7299166B2 (ja) * 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド 沈殿抵抗性低分子薬物製剤
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
JP2021509677A (ja) 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN111529489A (zh) * 2020-04-17 2020-08-14 山东省药学科学院 一种含有地西泮的鼻腔喷雾剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934078T3 (da) * 1996-10-24 2003-04-14 Alza Corp Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf
MXPA02001612A (es) * 1999-07-26 2003-10-14 Sk Corp Composiciones anti-convulsivas transnasales y procedimiento modular.
ATE401105T1 (de) * 2002-09-03 2008-08-15 Pharmacure Health Care Ab Nasensprays
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
JP5539875B2 (ja) * 2007-08-31 2014-07-02 アルキメデス・デベロップメント・リミテッド 非水性医薬組成物
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2011034920A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders

Also Published As

Publication number Publication date
US20170151258A1 (en) 2017-06-01
EP2691100A4 (en) 2014-09-24
CA2831308A1 (en) 2012-10-04
US20140128381A1 (en) 2014-05-08
AR085927A1 (es) 2013-11-06
PH12017501688A1 (en) 2018-09-10
TWI601532B (zh) 2017-10-11
US20120252793A1 (en) 2012-10-04
JP2014509655A (ja) 2014-04-21
KR20140029426A (ko) 2014-03-10
RU2018135967A (ru) 2018-11-14
HK1195252A1 (zh) 2014-11-07
WO2012135619A3 (en) 2012-11-22
CN103619338B (zh) 2016-06-22
SG10201602176RA (en) 2016-04-28
WO2012135619A2 (en) 2012-10-04
MX357800B (es) 2018-07-25
BR112013024968A2 (pt) 2016-12-20
TW201302204A (zh) 2013-01-16
EP2691100A2 (en) 2014-02-05
AU2012236334B2 (en) 2017-02-16
CN103619338A (zh) 2014-03-05
RU2013148120A (ru) 2015-05-10
AU2012236334A1 (en) 2013-10-10
SG193958A1 (en) 2013-11-29

Similar Documents

Publication Publication Date Title
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
HK1246674A1 (zh) 犬尿氨酸-3-單加氧酶抑制劑、藥物組合物及其使用方法
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
IN2014MN00948A (es)
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
MY173215A (en) Acetylcysteine compositions and methods of use thereof
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
NZ701607A (en) Therapeutic use of chardonnay seed products
EP2776059A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PROTEASES AND METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
MX2015011614A (es) Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia.
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
IL232157A0 (en) Implantable drug delivery preparations and treatment methods thereof
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MY160753A (en) Pharmaceutical composition in the form of an oral suspension comprising a flavonoid fraction and xanthan gum
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
HK1200101A1 (en) Therapeutic combination of memantine and baclofen and pharmaceutical composition containing them
GB201112739D0 (en) Production and administration of therapeutic agents
UA53217U (en) Mask for therapy and general health improvement

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: SK BIOPHARMACEUTICALS CO., LTD.